July 22, 2020
BlueSphere Bio has appointed a veteran drug development leader, Michael Geffner, M.D., M.B.A., as the company’s first chief medical officer.
July 9, 2020
Members of the scientific advisory board include Carl June, M.D., Ulrich von Andrian, M.D, Greg Delgoffe, Ph.D, and Marc Jenkins, Ph.D.
July 31, 2019
With Pitt Expertise and UPMC Funding, BlueSphere’s TCXpress Platform to Develop Rapid, Personalized T-Cell Therapies for Cancer Treatment.